NCT07821398Not yet recruitingPhase 2
Hyperpolarized Xenon MRI in Adults With Pulmonary Hypertension in Interstitial Lung Disease and Systemic Sclerosis
Harmonized Hyperpolarized 129Xe MRI for Noninvasive Assessment of Pulmonary Hypertension in Interstitial Lung Disease and Systemic Sclerosis (ILD-PH/SSc)
Source: ClinicalTrials.gov · Last updated 15 Sept 2026
Brief summary (registry, in English)
This study aims to evaluate a noninvasive magnetic resonance imaging technique using hyperpolarized xenon gas to measure lung function in adults with interstitial lung disease, pulmonary hypertension, and systemic sclerosis. Researchers will assess whether MRI measurements correlate with clinical measures of lung and vascular function.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 51 (estimated)
- First submitted
- 10 Sept 2026
- Start date
- 1 Nov 2026
- Primary completion date
- 20 Apr 2030
- Lead sponsor
- Bastiaan Driehuys
- NCT number
- NCT07821398
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 51
- From 1 Nov 2026 to the primary completion date, 20 Apr 2030
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent enrollment and participation in a study which, in the opinion of the Investigator, would interfere with the study compliance, or outcome assessments or would prohibit the collection of the required data points.
Other illness
- Any condition which, in the opinion of the Investigator, would make it unsafe or unsuitable for the participants to undergo MRI (for example: presence of an implanted or external MRI unsafe device that cannot be removed, body weight exceeding table limitations, inability to lie flat, or severe claustrophobia).
- Active pulmonary infection or lung cancer.
- Recent respiratory infection or pulmonary disease exacerbation within 4 weeks of screening.
Other
- Inability to hold breath for 10-15 seconds for required imaging or for completion of DLCO measurements.
- Participants who are known to be pregnant or lactating.
Who the study is looking for
- Age ≥18 years at enrollment.
- Participant is willing and able to provide written informed consent.
- Able (in the Investigator's opinion) and willing to comply with all study requirements.
- Participant has or is suspected to have one of the following pulmonary conditions:
- Healthy volunteers: aged 18-30 years; no known cardiopulmonary disease; has not smoked tobacco products in the previous 5 years; smoking history, if any, is less than or equal to 5 pack-years; no history of using other inhaled products more than 1 time per week for \> 1 year OR
- ILD-PH: ≥18 years; ILD diagnosis; precapillary PH by RHC (mPAP \>20 mmHg, PVR \>2 WU, PCWP ≤15 mmHg) within the specified window OR
- SSc: systemic sclerosis diagnosis with or without PH
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.